Chest
Preliminary ReportA Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism
Section snippets
Patients
The study population consisted of patients with acute symptomatic pulmonary embolism documented by either pulmonary angiography, or a high probability ventilation-perfusion lung scan (defined as a segmental or greater perfusion defect with ventilation mismatch21), plus deep vein thrombosis confirmed by venography or B-mode ultrasonography. Patients were excluded if they had an active bleeding process, active peptic ulcer disease, familial or acquired bleeding diathesis, or a platelet count
Patient Population
Fifty-eight patients with acute pulmonary embolism were randomized to either rt-PA (33 patients) or placebo (25 patients). The presenting symptom in patients who received rt-PA was chest pain in 20 (60.6 percent), dyspnea in 27 (81.8 percent), hemoptysis in five (15 percent), while six (18 percent) had syncope. In the placebo group, chest pain was experienced by 23 (92 percent), dyspnea in 22 (88 percent), hemoptysis in seven (28 percent), and five (20 percent) presented with syncope.
ACKNOWLEDGMENTS
We gratefully acknowledge the support of the members of the Departments of Medicine, Radiology and Nuclear Medicine at Henderson General Hospital and Hamilton General Hospital, Hamilton, Ontario and Hotel Dieu Hospital, Montreal, Quebec; the contribution of the hematology laboratories at the participating centers; the support of the study coordinator, M. Klimek, and study nurses is also recognized.
References (31)
- et al.
Kinetics of the activation of plasminogen by human tissue plasminogen activator
J Biol Chem
(1982) - et al.
Acute pulmonary embolism treated with tissue plasminogen activator
Lancet
(1986) - et al.
Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
Lancet
(1988) - et al.
The thrombolytic and hemorrhagic effects of tissue-type plasminogen activator: influence of dosage regimens in rabbits
Thromb Res
(1985) - et al.
Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits
Blood
(1985) - et al.
Bolus alteplase
Lancet
(1989) - et al.
Single bolus injection of recombinant tissue-type plasminogen activator (rt-PA) in acute myocardial infarction
Am J Cardiol
(1989) - et al.
Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction. Results of a multicentre randomized trial of two dosage regimens
J Am Coll Cardiol
(1990) - et al.
Venous thromboembolism
(1981) Phase I results
JAMA
(1970)
Phase II results
JAMA
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism
Chest
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells
J Pharm Exp Therapy
Cloning and expression of human tissue-type plasminogen activator cDNA in E coli
Nature
Tissue-type plasminogen activator: therapeutic potential in thrombotic disease states
Drugs
Cited by (279)
Safety and efficacy of clot-dissolving therapies for submassive pulmonary embolism: A network meta-analysis of randomized controlled trials
2024, Cardiovascular Revascularization MedicineBreaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen
2022, Journal of Thrombosis and HaemostasisAccelerated treatment with rtPA for pulmonary embolism induced circulatory arrest
2021, Thrombosis ResearchCurrent Controversies in Caring for the Critically Ill Pulmonary Embolism Patient
2020, Emergency Medicine Clinics of North America
Supported in part by the Ontario Ministry of Health and the Heart and Stroke Foundation of Ontario.